Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent's lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck's blockbuster med Keytruda in a pivotal head-to-head study.

MedCity News

30.10.2024

A CEO’s Guide to AI Exploration: Transforming Organizations and Mindsets - MedCity News

Try a variety of LLM-based tools yourself. Understand the risks, limitations, and who is working on putting quality frameworks and guardrails in place. Engage your employees and partners in discussions about what might now be possible.

MedCity News

30.10.2024

VBC, MA, FHIR and Modern Care - MedCity News

We know from everyday purchasing of goods and services that you have to combine what you’re getting with what you’re paying for that good or service. But how does this basic consumer supplier concept play out in US healthcare?

MedCity News

30.10.2024

MedCity FemFwd: How Doulas Can Improve Maternal Health Outcomes - MedCity News

In this episode, we’re joined by Dr. Tiffany Inglis, national medical director for women and children’s health at Carelon Health, a subsidiary of Elevance Health. Inglis discusses a paper Elevance Health Public Policy Institute recently published about doulas.

home›MedCity News

MedCity News

Health

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy - MedCity News

A CEO’s Guide to AI Exploration: Transforming Organizations and Mindsets - MedCity News

VBC, MA, FHIR and Modern Care - MedCity News

MedCity FemFwd: How Doulas Can Improve Maternal Health Outcomes - MedCity News

home
›
MedCity News